CHICAGO, July 26,
2024 /PRNewswire/ -- The Alzheimer's Association is
disappointed by today's decision by the European Medicines Agency
(EMA) to recommend against allowing Leqembi® to be
marketed across the European Union.
"The EMA has denied people living with Alzheimer's and their
families more time," said Joanne
Pike, DrPH, Alzheimer's Association president and CEO. "This
decision is out of step with the state of the science, and the
decisions of the U.S., Chinese, South Korean, Israeli, Hong Kong and Japanese regulatory
agencies."
The Alzheimer's Association hopes individual health agencies in
these countries will reject today's opinion and allow their
citizens the opportunity to access treatment for this devastating,
fatal disease.
"It is wrong. People living with Alzheimer's in some parts of
the world are able to benefit from scientific advancements, while
others are denied the opportunity. This decision by the EMA will
deepen an already emerging global health inequity in Alzheimer's
disease," Pike said.
While not a cure, this treatment can slow progression of the
disease when taken in the early stages of Alzheimer's, allowing
people more time to participate in daily life and live
independently. Leqembi was granted traditional approval by the U.S.
Food and Drug Administration (FDA) in July
2023.
Alzheimer's Association®
The Alzheimer's
Association leads the way to end Alzheimer's and all other dementia
— by accelerating global research, driving risk reduction and early
detection, and maximizing quality care and support. Our vision is a
world without Alzheimer's and all other dementia®. Visit
alz.org or call the 24/7 Helpline at 800.272.3900.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alzheimers-association-statement-on-european-medicines-agency-negative-opinion-on-leqembi-for-the-treatment-of-alzheimers-disease-302207754.html
SOURCE Alzheimer's Association